Figure 6.
ID2 inhibits tumor growth in multiple mouse xenograft models and demonstrates superior anti-tumor activity compared to the IR mAb/FcD2 combination. Tumor bearing mice were treated with controls and ID2 by intraperitoneal injection 3 times per week. The figure shows tumor volume (in mm3) as a function of treatment time (in days). The models tested were: (A) MiaPaCa-2; (B) HT-29; (C) Caki-1; (D) Colo-205. Tumor volume is plotted as mean ± SEM (n = 12). For statistical analysis, RM ANOVA was used through the last day of each study to compare the tumor growth between ID2 and other treatments. Levels of statistical significance are indicated as: *p = 0.01–0.05; ***p = 0.0001–0.001; ****p < 0.0001.